Nonalcoholic Steatohepatitis: KOL Insight Which NASH products are most likely to succeed as the new treatment paradigm develops?
At this stage of the game, it's unclear if one drug is going dominate the market. With significant clinical unmet need, plenty of room exists for diverse approaches. Nonalcoholic Steatohepatitis: KOL Insight reveals critical US and European KOL views on pipeline products, biomarkers, combination therapy, prescribing decision factors and what they see as emerging clinical benefits and challenges. Learn more.
GlaxoSmithKline announced Sunday that it reached an agreement with the UK Department of Health that will allow infants in the UK to receive its meningococcal serogroup B (MenB) vaccine Bexsero through... Read More >>